Roche Pharmaceuticals is focused on translating excellence in science into effective medicines for patients. It combines cutting-edge research at Roche,Genentech,in the US Chugaiin Japan and over 250 partners worldwide with global scale and reach in clinical development, manufacturing and commercial operations.

Thanks to the Pharma Division's broad-based portfolio, Roche is one of the world's leading providers of clinically differentiated medicines.

Roche Pharma is living proof that scientific invention leads to products that truly save and improve patients’ lives. Our inspiring tradition of excellence in science dates back more than a century. Today, as then, our strategy is rooted in fostering excellence in scienceand empowering scientists to create breakthroughs in life science that will make a difference tomorrow.

Focusing on oncology, immunology, ophthalmology, infectious diseases, neuroscience and rare diseases, we firmly believe in the tremendous potential to translate science into therapies which reduce human suffering and help people live longer and healthier lives.

In our pursuit of excellence in science, our distinctiveness rests on four key elements: an exceptionally broad and deep understanding of disease biology, the seamless integration of our pharmaceuticals and diagnostics capabilities, a diversity of approaches to maximise innovation, and a long-term orientation.

Cancer remains the second leading cause of death in the industrialised world and its incidence is growing. But if detected early enough, many forms of the disease can be effectively treated. We have been at the forefront of cancer research and treatment for over 50 years. Our medicines treat breast,skin,ovarian,lungand numerous other cancers.They give patients the most important thing in life: time to live.

More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines. By developing products that advance the standard of care for diseases with significant unmet need we are able to meet our obligations not only to shareholders but to society as a whole.